What is Arcutis Biotherapeutics, Inc.'s accrued final fee?

Arcutis Biotherapeutics, Inc. (ARQT) reported accrued final fee of $9.22M in Q1 2026.

How has Arcutis Biotherapeutics, Inc.'s accrued final fee changed year-over-year?

Arcutis Biotherapeutics, Inc.'s accrued final fee increased by 20.1% year-over-year, from $7.68M to $9.22M.

Revenue$105.4M+60.1%

Gross profit$95.6M+67.7%

Operating income-$9.1M+62.9%

Net income-$11.3M+54.9%

EPS (diluted)-$0.09+55.0%

Cash & equivalents$35.1M-34.7%

Total debt$114.7M+3.5%

Total equity$189.6M+32.9%

Total assets$460.0M+33.7%

Operating cash flow$2.2M+107%

CapEx--100%

Free cash flow$2.2M+107%

Market cap$3.29B+57.5%

Gross margin90.9%+2.5pp

Operating margin-12%-5.7pp

Net margin-13.9%-6.6pp

FCF margin-52.5%-21.9pp

Return on equity-28.2%-13.0pp

Debt / equity0.6×-0.2×

Current ratio2.7×-0.9×

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept arqt:DebtInstrumentAccruedFinalFee.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

What is Arcutis Biotherapeutics, Inc.'s accrued final fee?: Arcutis Biotherapeutics, Inc. (ARQT) reported accrued final fee of $9.22M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s accrued final fee changed year-over-year?: Arcutis Biotherapeutics, Inc.'s accrued final fee increased by 20.1% year-over-year, from $7.68M to $9.22M.